Origin Materials, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Origin Materials, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.92M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $31.28M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $28.81M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 5, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($249.70M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($83.70M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $23.80M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $78.57M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $42.09M | Feb 23, 2023 |
| FY2020 | Dec 31, 2020 | ($25.87M) | May 3, 2021 |
| FY2020 | Sep 30, 2020 | ($4.89M) | May 3, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($259.09M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($84.86M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($54.88M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($38.95M) | Mar 5, 2024 |
| FY2020 | Dec 31, 2020 | ($3.03M) | May 3, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.75M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $18.55M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $21.35M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $14.14M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $9.12M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $4.14M | Feb 23, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($32.79M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($50.83M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($60.36M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($26.09M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($22.04M) | Feb 23, 2023 |
| FY2020 | Dec 31, 2020 | ($562.3K) | May 3, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.21M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.95M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $102.19M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $83.69M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $12.27M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $1.79M | Feb 23, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.66M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $378.03M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $461.83M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $493.70M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $510.42M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $47.43M | Mar 1, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.45M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $39.66M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $39.33M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $116.80M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $206.91M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $47.31M | Mar 1, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.21M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $338.37M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $422.51M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $376.91M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $303.51M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $123.0K | Feb 23, 2023 |
| FY2020 | Jan 23, 2020 | $0 | May 3, 2021 |
| FY2022 | Dec 31, 2019 | $28.00M | Feb 23, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($287.83M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($38.13M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $45.57M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $21.77M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($56.80M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($98.89M) | Mar 1, 2022 |
| FY2020 | Sep 30, 2020 | ($4.89M) | May 3, 2021 |
| FY2020 | Jul 16, 2020 | ($2.71M) | May 3, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.92M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $56.31M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $75.50M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $107.86M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $46.64M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.31M | Mar 1, 2022 |
| FY2020 | Jan 23, 2020 | $0 | May 3, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (50) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (50) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | 0 | Feb 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.17M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 4.95M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 145.71M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 143.03M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 141.30M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 70.27M | Mar 1, 2022 |